{"id":394831,"date":"2023-12-22T19:00:00","date_gmt":"2023-12-23T00:00:00","guid":{"rendered":"https:\/\/platohealth.ai\/role-of-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-high-risk-t-cell-lymphoblastic-leukaemia-lymphoma-an-analysis-of-clinical-outcomes-bone-marrow-transplantation\/"},"modified":"2023-12-23T10:20:50","modified_gmt":"2023-12-23T15:20:50","slug":"role-of-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-high-risk-t-cell-lymphoblastic-leukaemia-lymphoma-an-analysis-of-clinical-outcomes-bone-marrow-transplantation","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/role-of-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-high-risk-t-cell-lymphoblastic-leukaemia-lymphoma-an-analysis-of-clinical-outcomes-bone-marrow-transplantation\/","title":{"rendered":"Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia\/lymphoma: an analysis of clinical outcomes – Bone Marrow Transplantation","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
  • \n

    Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114:5136\u201345.<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n     PubMed<\/a> 
    \n     PubMed Central<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2004;22:4075\u201386.<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Yang L, Tan Y, Shi J, Zhao Y, Zhu Y, Hu Y, et al. Correction: Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma. Bone Marrow Transplant. 2020;55:2056.<\/p>\n

    Article<\/a> 
    \n     PubMed<\/a> 
    \n     PubMed Central<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Bazarbachi A, Labopin M, Angelucci E, G\u00fclbas Z, Ozdogu H, Arat M, et al. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2020;26:936\u201342.<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993. Blood. 2006;108:465\u201372.<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n     PubMed<\/a> 
    \n     PubMed Central<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Eckert C, Parker C, Moorman AV, Irving JAE, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175\u201389. (1990)<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n     PubMed<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Liang D, Wei C, Zhang X, Yang J, Zheng Y, Du J, et al. Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma\/leukemia after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2021;62:2521\u20135.<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n     PubMed<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang M-J, Wang H-L, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3:670\u201380.<\/p>\n

    Article<\/a> 
    \n     PubMed<\/a> 
    \n     PubMed Central<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet. Haematol. 2020;7:e157\u2013e167.<\/p>\n

    Article<\/a> 
    \n     PubMed<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Wei C, Zhang X, Liang D, Yang J, Du J, Yue C, et al. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients. Drug Design, Development and Therapy. 2021;15:4875\u201383.<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n     PubMed<\/a> 
    \n     PubMed Central<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n

  • \n

    Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489:155\u20139.<\/p>\n

    Article<\/a> 
    \n     CAS<\/a> 
    \n     PubMed<\/a> 
    \n     PubMed Central<\/a> 
    \n
    \n Google Scholar<\/a> \n <\/p>\n<\/li>\n